EmailHospital Circular 09/2004
Date Issued: 29 March 2004
Distribution: Public Hospitals
Subject: Highly Specialised Drugs Program
Purpose: To advise hospitals of changes to the Highly Specialised Drugs Program, effective 1 April 2004.
We have had recent advice from the Australian Government of changes to the Highly Specialised Drugs Program, effective 1 April 2004.
ADD DRUG
Sirolimus
CAUTION:
Careful monitoring of patients is mandatory.Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis and treatment of renal allograft rejection. Management includes initiation, stabilisation and review of therapy as required.
| 6346R | Tablet 1mg | 100 | $670.00 | Rapamune | WY |
| 6437T | Oral solution 1mg per mL | 1 | $402.00 | Rapamune | WY |
Changes notified by hospital circular will be updated in the Guidelines on the Commonwealth/State Highly Specialised Drugs Program Guidelines website and the claim form amended.
Noreen Dowd
Director, Programs
Metropolitan Health & Aged Care Services
